PEGBIO CO-B-50(02565): CR059 will receive acceptance for EASD 2026 and be included in the oral presentation discussion session.

PEGBIO CO-B-50(02565) Announcement: The research results of the group's independently developed circular RNA encoding GLP-1 analogue CR059 has been accepted by the 62nd European Association for the Study of Diabetes Annual Meeting 2026 ("EASD 2026") and selected for an oral presentation. Following the selection of CR059-related research results for the Late-Breaking Abstract of the American Diabetes Association Scientific Sessions ("ADA Annual Meeting"), this acceptance and selection for oral presentation at EASD 2026 further highlights the high attention and recognition received by CR059 and the group's circular RNA technology platform in the global field of diabetes and metabolic diseases. The selected research topic for this presentation is "Single-dose CR059, a circular RNA-encoded GLP-1 analogue, enables sustained exposure and prolonged body weight reduction in non-human primates". CR059 is a new generation GLP-1 analogue developed by the group based on its proprietary circular RNA technology platform. It aims to achieve sustained drug exposure and long-term metabolic regulation effects by continuously expressing GLP-1 analogues in the body through circular RNA encoding. This project explores a new drug model for long-term treatment of metabolic diseases through circular RNA encoding expression mechanism, different from the traditional peptide GLP-1 receptor agonist-dependent extended drug half-life pathway. It represents an innovative therapeutic direction with frontier attributes, platform scalability, and intergenerational upgrade potential. The core innovation value of CR059 lies in its potential to break through the current treatment mode of existing GLP-1 drugs primarily administered weekly, further expanding towards ultra-long-term treatment intervals of monthly or even quarterly intervals. If successful in subsequent clinical translation, such a technological pathway is expected to significantly reduce the long-term drug burden for patients with chronic metabolic diseases, improve treatment compliance and long-term management efficiency, and provide a new generation solution distinct from existing peptide drugs for obesity, type 2 diabetes, and related metabolic diseases. EASD Annual Meeting is one of the most influential international academic conferences in the field of diabetes and metabolic diseases, jointly with the ADA Annual Meeting serving as the most important international academic exchange platform in this field. Oral presentations at EASD Annual Meeting are important showcases granted by the scientific committee after selection, typically targeting research results with high innovativeness, scientific value, and field attention. The selection of CR059 research results for this showcase demonstrates the strong international academic appeal of the project in terms of new drug models, ultra-long-term action mechanisms, and potential clinical applications. The acceptance and selection of CR059 research results for oral presentation at EASD 2026, following the previous selection for ADA Late-Breaking Abstract, represents another important milestone achieved by the group in the global next-generation metabolic disease innovative drug development field. This progress not only reflects the cutting-edge and differentiation potential of the CR059 project itself but also further validates the application value and international competitive potential of the group's circular RNA technology platform in the direction of long-term and ultra-long-term treatment of metabolic diseases. The group already has a marketed long-acting GLP-1 receptor agonist, semaglutide injection, and continues to expand its portfolio with innovative therapies for metabolic diseases led by CR059. The continued progress of CR059 will help the group to evolve from an established GLP-1 innovative drug enterprise to a metabolic disease innovative drug enterprise covering weekly formulations, monthly or longer and quarterly ultra-long-term GLP-1 technology pathways, possessing platform-based research and development capabilities and global academic influence. The company believes that these advancements will further enhance the group's technical recognition, academic reputation, pipeline value, and potential international collaboration opportunities in the global field of metabolic disease drug development.